Please login to the form below

Not currently logged in

CMPT announces CEO and loan investment

CMP Therapeutics has announced that Dr Neill Moray Mackenzie will become CEO and that the company will receive a €1.5m convertible loan investment

CMP Therapeutics (CMPT) has appointed Dr Neill Moray Mackenzie to the role of CEO, replacing Dr Bruce Savage, who leaves CMPT to concentrate on his other portfolio companies.

Dr Mackenzie brings to CMPT experience at executive board level in both the biotechnology and pharmaceutical industries. He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji (London).

Dr MacKenzie was also a departmental head in vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

In addition, CMPT has announced that the company will receive an injection of €1.5m in the form of a convertible loan from Inventages Venture Capital, which will be used to support continuing operations and the upcoming clinical trial of its lead product for the common cold.

Since 2005 CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures.

2nd August 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....